Synthon's most advanced pipeline program is SYD985, an ADC targeting a range of HER2-positive cancers such as (metastatic) breast cancer, gastric cancer, bladder (urothelial) cancer and endometrial (uterine) cancer.

About trial SYD985.001

Trial SYD985.001 is a two part first-in-human Phase I study with the anti-HER2 ADC SYD985 to evaluate the safety, pharmacokinetics and efficacy in patients with histologically-confirmed, locally advanced or metastatic tumors. These are patients who have progressed on standard therapy or for whom no standard therapy exists.

During part I (dose escalation), patients with solid tumors of any origin were enrolled (so called 'all comers'). For part II (expanded cohorts), enrollment includes patients with breast or selected non-breast tumors with demonstrated HER2 expression and measurable disease lesions, which are predefined in the protocol. This trial is registered in with identifier NCT02277717.

If you have any questions, please contact us

SYD985 data shared

The encouraging clinical results obtained in the first (dose-escalation) part of the clinical trial with SYD985 were presented at several renowned venues.

Scientific publications

SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody-Drug Conjugate, Shows Antitumor Activity in Uterine Serous Carcinoma with HER2/Neu Expression (Mol. Cancer Therapeutics, 2016/8)

Design, Synthesis, and Evaluation of Linker-Duocarmycin Payloads: Toward Selection of HER2-Targeting Antibody-Drug Conjugate SYD985 (Mol. Pharmaceutics, 2015/12)

The Preclinical Profile of the Duocarmycin-Based HER2-Targeting ADC SYD985 Predicts for Clinical Benefit in Low HER2-Expressing Breast Cancers (Mol. Cancer Therapeutics 2015/3)

Preclinical Profile of the HER2-Targeting ADC SYD983/SYD985: Introduction of a New Duocarmycin-Based Linker-Drug Platform (Mol. Cancer Therapeutics 2014/11)

partner with Synthon
     Share this page